GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling ‘illegal’ products
A Reformed FDA Under Trump Likely Means Uncertainty
Our editorial staff contemplates what 2017 has in store for healthcare marketers, and we forsee big changes and some setbacks in the ongoing shift toward a data-driven, value-based industry.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix